SLC5A2 and diabetes mellitus: Scientific investigation has shown that other SGLT2 inhibitors, such as canagliflozin (1) and dapagliflozin, also have protective effects on the cardiovascular health of diabetes mellitus (DM) type 2 sufferers (2).